Biotech Values

[mcbio]

Re: partnering of PMX-60056

This is a far-fetched premise, IMO. For all practical purposes, the LMWH market consists of exactly one product: Lovenox, which could soon be available as a generic (:- ))

Fragmin and the other non-Lovenox LMWH’s are non-factors in the marketplace, and I consider it highly unlikely that these drugs could see meaningful commercial uptake this late in the game even if there were clinical data on their reversibility with PMX-60056.

In other words, there are zero “LMWH companies” who are logical partners for PMX-60056, IMO.

So why couldn't PMX-60056 theoretically be partnered with SNY or, better yet, Sandoz/MNTA?